A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 11 Dec 2018 Planned End Date changed from 1 Nov 2021 to 1 Jan 2022.
- 11 Dec 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Jan 2021.